Table 5 Knowledge of pharmacovigilance and ADR reporting among the participants (n = 450)
Question | Yes N (%) | No N (%) | I don't Know N (%) |
|---|---|---|---|
Definition of pharmacovigilance | 475 (99.4) | 3 (0.6) | Â |
Definition of ADR | 475 (99.4) | Â | 3 (0.6) |
ADR and ADE are different | 382 (79.9) | 51 (10.7) | 45 (9.4) |
Yellow form is a tool for reporting ADR in Nigeria | 365 (76.4) | 5 (1.0) | 108 (22.6) |
Pharmacovigilance center, through NAFDAC, regulates ADR reporting in Nigeria | 416 (87.0) | 10 (2.1) | 52 (10.9) |
Classes of ADRs include (i) dose-related, (ii) allergic, and (iii) idiosyncratic | 435 (91.0) | 21 (4.4) | 22 (4.6) |
Most important purpose of PV is to ensure safety of drugs | 456 (95.4) | 8 (1.7) | 14 (2.9) |
All severe ADRs of drugs are known before a drug is marketed | 238 (49.8) | 227 (47.5) | 13 (2.7) |
ADRs previously documented by manufacturers need not be reported again | 216 (45.2) | 207 (43.3) | 55 (11.5) |